glp 1 drugs oral list inhibitors Are Serious Anesthesia Risks of Semaglutide and Other GLP-1 Agonists Under GLP-1 Receptor Agonist Shortage: Challenges
Description
This success in obesity treatment has naturally led researchers to explore their potential in other metabolic disorders, including liver diseases like MASH
Sun Y, Jin J, Zhu A, et al
doi: 10.18632/oncotarget.13189
11.3% of patients had an age 65 years old
For comorbid metabolic diseases, such as diabetes and obesity, the use of GLP-1RAs generally does not increase cancer risk and may offer certain benefits
